EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

THOUSAND OAKS, Calif. and BRUSSELS, Oct. 17, 2019 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human U... Biopharmaceuticals, Regulatory Amgen, UCB, EVENITY, romosozumab, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news